Global Renal Anemia Treatment Market 2021 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Renal Anemia Treatment Market 2021 (Includes Business Impact of COVID-19)
Global Renal Anemia Treatment Market is an upcoming report created by market analysts at Trusted Business Insights. The target market is expected to be valued at US$ X.X Mn in 2019 and is projected to witness lucrative CAGR over the 10-year period. The global market report has been segmented on the basis of medicine type, route of administration, distribution channel, and region/ country.
Request Covid - 19 Impact
The global Renal Anemia Treatment market size was valued at USD$ 36.20 billion in 2020 and is projected to reach UDS$67.31 billion by 2030, and is anticipated to expand at a CAGR of 6.40% over the forecast period from 2020 to 2030.


Renal Anemia Treatment: Overview


Renal Anemia is a chronic condition caused due to low count of red blood cells (RBC) or minimal oxygen carried by RBC to organs and tissues, specifically brain and heart. On the basis of etiology, anemia is categorized into three types such as blood loss, low RBC production, and high RBC destruction. Patients suffering from chronic kidney disease (CKD), commonly get anemia. When kidneys do not function appropriately or are damaged, they are unable to produce required amount of erythropoietin hormone, which plays vital role in production of red blood cells. This can result in less production of RBC by bone marrow, causing anemia. Some of the common causes include low iron level, folic acid, and vitamin B12; chronic infections, issues related to bone marrow, and malnutrition. Renal anemia is mostly diagnosed by examining medical history and blood tests among other options.
Dynamics:

Market Growth Drivers, Trends and Threats


Increasing number of patients with CKD, rising number of kidney transplants among people due to permanent or partial loss of kidney functions are major factors expected to drive growth of the global market.

Increasing prevalence of kidney diseases wherein they get damaged due to blood loss from hemodialysis or due to less consumption of nutritional content such as iron, vitamin B12, and folic acid is another major factor expected to drive growth of the global market. Increasing investments by certain major companies on R&D of enhanced drugs and launch of medicines to overcome anemia is expected to drive market growth. For instance, Novartis launched its new product -Binocrit “ for renal anemia treatment associated with chronic renal failure.

However, high cost of drugs and potential side-effects such as chronic blood pressure issues and thromboembolic complications are major factors that could hamper growth of the target market. Moreover, consumption of erythropoiesis-stimulating agents by cancer patients can augment growth of tumor, which is another factor that could challenge market growth.


Segment Analysis By Medicine Type:


Among the type segments, the erythrocyte stimulating agents and iron supplements segments are expected to contribute higher shares in terms of revenue.


By Route of Administration:


Among the route of administration segments, the parenteral segment is estimated to account for major share in terms of revenue and adoption rate, as healthcare professionals prefer injectable route of administration of medicines for renal anemia.


By Distribution Channel:


Among the segments based on distribution channel, the retail pharmacy segment is anticipated to account for moderate share in terms of revenue owing to easy and faster accessibility to 24-hour pharmacies. The online pharmacy segment is anticipated to grow at a significant CAGR owing to rising preference for purchasing medicines online at discounted prices.

Regional Analysis

The North America market accounted for the largest share in terms of revenue in the global market, owing to presence of major players, coupled with rising investments in R&D activities for development of new, enhanced, and innovative drugs. In addition, rising prevalence of chronic kidney diseases due to unhealthy eating and drinking habits is another factor expected to support growth of the NA market. The APAC renal anemia treatment market is projected to register the highest growth rate owing to rapidly flourishing healthcare sector, rising medical tourism, and rising number of patients suffering from anemia, and need for treatment of kidney-related diseases. The MEA and Latin America markets are expected to grow at a moderate growth rate in the next 10 years.

Global Renal Anemia Treatment Market Segmentation:

Segmentation by Medicine Type:

  
Iron Supplements
  
Erythrocyte Stimulating Agents
  
Red Blood Cell Transfusions
  
Vitamin B 12 and Folic Acid Supplements

Segmentation by Route of Administration:

  
Oral
  
Parenteral

Segmentation by Distribution Channel:

  
Hospital Pharmacy
  
Retail Pharmacy
  
Online Pharmacy


Key Market Players included in the report:


  
Akebia Therapeutics
  
Alaven Pharmaceutical LLC
  
AMAG Pharmaceuticals
  
Amgen.
  
Contract Pharmacal Corp
  
F. Hoffmann-La Roche Ltd
  
Hoffmann-La Roche Ltd
  
Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  
Keryx Biopharmaceuticals
  
Pfizer Inc.
  
Rockwell Medical
  
Sandoz International GmbH (Novartis AG)
  
Teva Pharmaceutical Industries Ltd.
  
Vifor Pharma Management Ltd.


Below are the key development related to Renal Anemia Treatment Market in 2020 and 2021.


May 2021: Diaverum acquires booknowmed.com. Diaverum, a leading global renal care service provider, announces the acquisition of booknowmed.com, the world’s leading booking engine in renal care that enables patients to browse over 400 dialysis clinics across 54 countries and book their dialysis treatment in real-time, with no booking or cancellation fees. With its ‘patient-centric approach, this innovative booking engine has evolved into an easy-to-use, interactive platform for the renal care community. booknowmed.com is an official holiday dialysis partner of 60 Kidney Patient Associations in 20 countries, organizing group and individual trips for their members every year. Source

November 2020: Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis. Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis. Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") announced that Japans Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO® (roxadustat) for the treatment of anemia of chronic kidney disease (CKD) in adult patients not on dialysis. This marks the second approval in Japan for roxadustat through the Astellas and FibroGen collaboration, after the therapy was approved and launched for use in adult patients with anemia of CKD on dialysis last year. Source

June 2020: Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease. Study meets primary endpoint demonstrating non-inferiority of roxadustat to darbepoetin in correction and maintenance of hemoglobin levels. Findings presented in oral session at the European Renal Association-European Dialysis and Transplant Association Virtual Congress 2020. Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced results from the Phase 3 DOLOMITES study, evaluating the efficacy and safety of roxadustat compared with darbepoetin alfa for the treatment of anemia in non-dialysis dependent (NDD) adult patients with stage 3–5 chronic kidney disease (CKD) (Abstract: MO001). The data presented during an oral presentation at the 57th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress, taking place between June 6–9, 2020, showed non-inferiority of roxadustat to darbepoetin alfa in the correction of hemoglobin levels during the first 24 weeks of treatment (89.5% vs 78.0%; a difference of 11.51% [95% confidence interval (Cl): 5.66%, 17.36%]), meeting the studys primary endpoint with a lower bound of the 95% CI >0. Secondary endpoints were hierarchically tested for non-inferiority and superiority. Superiority of roxadustat to darbepoetin alfa was demonstrated by a decrease in low-density lipoprotein cholesterol with a least square mean (LSM) difference of –0.403 mmol/L (95% CI –0.510, –0.296; [P<0.01]) and in time to first intravenous iron use with a hazard ratio (HR) of 0.45 (95% CI: 0.26, 0.78; [P=0.004]). The non-inferiority of roxadustat to darbepoetin alfa was demonstrated for mean arterial pressure with a LSM difference of –0.372 mmHg (95% CI: –1.587, 0.842) and time to occurrence of hypertension (HR=0.83; [95% CI: 0.56, 1.22]). Regarding safety, the overall incidence of treatment emergent adverse events was comparable between roxadustat and darbepoetin alfa (91.6% and 92.5%, respectively). A non-confirmatory analysis of adjudicated major adverse cardiovascular event (MACE)/MACE plus hospitalized unstable angina and hospitalized congestive heart failure (MACE+) outcomes showed HR point estimates of 0.81 (95% CI: 0.52, 1.25) and 0.90 (95% CI: 0.61, 1.32). Source

May 2020: Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis. Vadadustat achieved primary efficacy and cardiovascular safety endpoints. Clear, consistent top-line data advances plan for vadadustats New Drug Application and other global regulatory submissions. Company to discuss top-line data on its scheduled first quarter financial results conference call at 8:30 a.m. ET. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced positive top-line results from INNO2VATE, the first of its two global Phase 3 cardiovascular outcomes programs. The two INNO2VATE studies evaluated the efficacy and safety of vadadustat, Akebias investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Vadadustat achieved the primary and key secondary efficacy endpoint in each of the two INNO2VATE studies, demonstrating non-inferiority to darbepoetin alfa as measured by a mean change in hemoglobin (Hb) between baseline and the primary evaluation period (weeks 24 to 36) and secondary evaluation period (weeks 40 to 52). Vadadustat also achieved the primary safety endpoint of the INNO2VATE program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE), which is the composite of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke across both INNO2VATE studies. Each analysis was measured against non-inferiority (NI) margins agreed upon with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Source

January 2020: Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan. Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") announced the submission of a supplemental New Drug Application (sNDA) to Japans Ministry of Health, Labour and Welfare to gain marketing approval for Evrenzo® (generic name: roxadustat) for the treatment of anemia associated with chronic kidney disease (CKD) in non-dialysis dependent (NDD) patients. Roxadustat was approved in Japan for the treatment of anemia associated with CKD in dialysis dependent (DD) patients in September 2019 and launched for use in this indication in November 2019. The sNDA for the use of roxadustat in NDD-CKD patients is supported by three studies in more than 500 Japanese patients, which establish the profile within this group of patients. Source